Indian Journal of Obstetrics and Gynecology Research

Print ISSN: 2394-2746

Online ISSN: 2394-2754

CODEN : IJOGCS

Indian Journal of Obstetrics and Gynecology Research (IJOGR) open access, peer-reviewed quarterly journal publishing since 2014 and is published under auspices of the Innovative Education and Scientific Research Foundation (IESRF), aim to uplift researchers, scholars, academicians, and professionals in all academic and scientific disciplines. IESRF is dedicated to the transfer of technology and research by publishing scientific journals, research content, providing professional’s membership, and conducting conferences, seminars, and award more...

  • Article highlights
  • Article tables
  • Article images

Article statistics

Viewed: 119

PDF Downloaded: 18


Get Permission Kumari, Bala, and Pahwa: Lactate dehydrogenase as a biochemical marker for prediction of maternal and perinatal outcomes in hypertensive disorders in pregnancy


Introduction

Worldwide, hypertensive disorder in pregnancy [HDP] is one of the leading cause of maternal and perinatal death. According to the World Health Organization (WHO), 19% of maternal deaths are caused by hypertension disorder in pregnancy.1 Hypertensive disorder of pregnancy includes new onset hypertension in pregnancy that is gestational hypertension and already existing hypertension that is chronic hypertension and gestational hypertension sometimes worsened by preeclampsia. Preeclampsia can cause complications such as eclampsia, HELLP syndrome, renal failure, pulmonary edema, stroke, and left ventricular failure.2 In the Eclampsia Registry (2013), the prevalence of preeclampsia was found to be 10.3%.3 Hypertensive disorders are 4th most common cause of MMR.4

Abnormal trophoblast invasion, immune dysfunction, parental incompatibility, and genetics are among the many mechanisms of preeclampsia. Preeclampsia is more common in young and nulliparous women whereas chronic hypertension with superimposed preeclampsia is more common in older women.5

Every body cell contains LDH, an essential enzyme that is highly concentrated in key organs such as the heart, liver, muscles, kidneys, lungs, and RBCS.6 Its primary role is to support the anaerobic metabolic pathway, which turns glucose into energy. Higher serum LDH levels are associated with number of clinical problems and tissue damage, making it a important marker for diagnosing and monitoring a variety of diseases, including preeclampsia.6, 7

Serum levels of LDH are to be significantly elevated in preeclamptic patients and a correlation is observed between heightened LDH levels and severity of condition. Therefore, the routine measuring of serum LDH levels can assist clinicians to estimate the progression and severity of preeclampsia and also assessing feto-maternal poor outcomes.7, 8

Materials and Methods

This was a prospective study done in tertiary care c, after getting approval from the Institute Ethics Committee. The study was conducted from 01st January, 2023 To 31st March, 2024. The study included all antenatal women attending out-patient department (OPD) as well as emergency of tertiary care centre beyond 28 weeks gestation, willing to follow-up and give consent for the study. Patients were followed up till delivery and 6 weeks post-partum. Total 140 women were enrolled in the study after obtaining the written informed consent and obtaining clearance from ethical committee.

Inclusion criteria

  1. Singleton pregnancy

  2. After 28 weeks of gestation

Exclusion criteria

Patients with

  1. Diabetes

  2. Renal failure

  3. Previous h/o Haemolytic anemia

  4. Multiple pregnancy

  5. Smoking and alcoholism

  6. Liver disease

  7. Hepatotoxic drug

  8. Stroke, coronary artery disease

  9. Chronic lung disease connective tissue disorders

Upon meeting the inclusion criteria, a thorough obstetric history and examination were conducted for each enrolled patient. Blood pressure (BP) was measured using an LED mercury sphygmomanometer, with readings taken either in the sitting or supine position. The zero level of the apparatus was aligned with the level of the heart, and BP was assessed in both arms. A cuff that fit snugly around the arm was used: a standard cuff was employed for arm circumferences of 33 cm or less, while a larger cuff (15×35 cm) was used for arm circumferences greater than 33 cm. The lower edge of the cuff was positioned 2.5 cm above the antecubital fossa. First, systolic blood pressure was measured at the brachial artery using the palpatory method. Subsequently, it was measured using the auscultatory method at Korotkoff phase I for systolic pressure and Korotkoff phase V (K5) for diastolic pressure. If K5 was absent, diastolic pressure was recorded at Korotkoff phase IV. Routine laboratory tests included a complete blood count, ABORh, VDRL, Anti-HIV, Anti-HCV, HBsAg, oral glucose tolerance test (OGTT), random blood sugar, and a complete urine analysis. Additional laboratory tests included liver function tests, renal function tests, serum uric acid, serum lactate dehydrogenase, peripheral blood film, prothrombin time index, and either an on-spot urinary protein-to-creatinine ratio or urine albumin measured by the dipstick method. Fundoscopy was recommended for all enrolled patients. Serum LDH test was done in all the patients using L TO P-IFCC method with a reference range of 120-246 U/L.

Statistical Analysis: The data was collected systematically and edited after collection. The data was then entered into computer and statistical analysis of the results was obtained by using windows based computer software devised with Statistical Packages for Social Sciences (SPSS-22) (SPSSS Inc, Chicago, IL, USA). The results were presented in tables and graphs. Continuous variables were expressed as mean with standard deviation and categorical variables as count with percentage. Independent ‘t’ test, One Way ANOVA and Pearson’s correlation was used for data analysis in ICP and NON ICP patients.

1.  Mean (average) x = Total of the all values Number of valuesnn

 

2. Chi square

X2=(o-e)2e

Where 

o = observed value

e = expected value

3. Standard deviation of observation (S.D) =

s=(x-x-)2n-1

      

Where

x = mean x

n= number of observation

4. d.f = (column-1) (row-1)

Results

140 women were enrolled in the study after submitting informed consent and taking into account the inclusion and exclusion criteria.

Table 1

Distribution of study groups

Study groups

No. of cases

% age

Mild pre eclampsia

81

57.9

Severe pre eclampsia

51

36.4

Eclampsia

8

5.7

Total

140

100.0

Distribution of study participants according to the Serum LDH levels and Correlation With Blood Pressure.

Table 2

Correlation of serum LDH levels with systolic blood pressure

LDH (IU/L)

No.

Systolic blood pressure(mmhg)

Mean

SD

<600

74

143.86

10.800

601-800

40

152.40

14.551

>800

26

162.62

11.395

Total

140

149.79

13.980

p-value (ANOVA test)

0.001

In our study, patients with serum LDH levels <600 IU/L, the mean systolic blood pressure was 143.86 mmHg. For patients with serum LDH levels between 601-800 IU/L, the mean systolic blood pressure was 152.40 mmHg. In patients with serum levels of LDH exceeding 800 IU/L, the mean systolic blood pressure was not provided, but the p-value obtained was significant, indicating a statistically significant association between serum LDH levels and systolic blood pressure.

Table 3

Correlation of serum LDH levels with diastolic blood pressure

LDH (IU/L)

No.

Diastolic blood pressure (mmhg)

Mean

SD

<600

74

97.70

7.518

601-800

40

104.35

7.908

>800

26

110.69

6.424

Total

140

102.01

8.956

p-value (ANOVA test)

0.001

In our study patients with serum LDH levels <600 IU/L, the mean diastolic blood pressure was 97.70 mmHg. For patients with serum LDH levels between 601-800 IU/L, the mean diastolic blood pressure was 104.35 mmHg. The mean diastolic blood pressure for patients with serum levels of LDH exceeding 800 IU/L was not provided, but the p-value obtained indicated a significant association between serum LDH levels and diastolic blood pressure.

Distribution of study participants according to the serum LDH levels and correlation with maternal outcomes

Maternal outcome and LDH levels among study participants were cross-tabulated and analyzed, and it was found that the mean LDH level was 1303.600 ± 465.0186 IU in HELLP patients and 656.296 ± 322.7073 IU in non-HELLP patients. In patients experiencing abruption, the mean LDH level was 947.263 +/-403.6658 IU, while in those without abruption, it was 637.355 +/- 320.5428 IU. In patients with maternal mortality, the mean level of LDH was 321; in those without maternal mortality, it was 661.158.The statistical analysis of the data shows a statistically significant correlation (p < 0.05) between the study groups' LDH levels, HELLP syndrome, abruption, and maternal death.

Table 4

Correlation of serum LDH levels with Abruptio placenta

LDH (IU/L)

Abruptio placenta

Total

No

Yes

No.

%age

No.

%age

No.

%age

<600

71

58.68

3

15.79

74

52.86

601-800

34

28.10

6

31.58

40

28.57

>800

16

13.22

10

52.63

26

18.57

Total

121

100.00

19

100.00

140

100.00

Mean

637.355±320.542

947.263±403.665

679.414±348.0668

[i] p-value (Independent t-test) 0.001

In our study, we observed that among patients with serum LDH levels below 600 IU/L, 15.79% had abruptio placenta while 58.68% did not have abruption. For those with serum LDH levels between 601-800 IU/L, 31.58% had abruptio placenta and 28.10% did not have abruption. In patients with serum LDH levels exceeding 800 IU/L, 52.63% had abruptio placenta and 13.22% did not have abruption. The mean LDH level was 947.263 ± 403.6658 IU in patients with abruption and 637.355 ± 320.5428 IU in patients without abruption. In our study, we found a significant correlation between serum LDH levels and the occurrence of abruptio placenta.

Table 5

Correlation of serum LDH levels with hellp syndrome

LDH (IU/L)

HELLP Syndrome

Total

No

Yes

No.

%age

No.

%age

No.

%age

<600

74

54.81

0

0.00

74

52.86

601-800

39

28.89

1

20.00

40

28.57

>800

22

16.30

4

80.00

26

18.57

Total

135

100.00

5

100.00

140

100.00

Mean

656.296±322.703

1303.600±456.018

679.414±348.0668

p-value (Independent t-test)

0.001

In our study, we observed that no patient with serum LDH levels below 600 IU/L had HELLP syndrome. Among those with serum LDH levels between 601-800 IU/L, 20% had HELLP syndrome, while 28.89% did not. For patients with serum LDH levels exceeding 800 IU/L, 80% had HELLP syndrome, and 16.30% did not. The mean LDH level in patients with HELLP syndrome was 1303.600 ± 456.018 IU, significantly higher than the 656.296 ± 322.703 IU observed in patients without HELLP. Our study found a significant correlation between heightened serum levels of LDH and the occurrence of HELLP syndrome.

Table 6

Correlation of serum LDH levels with maternal mortality

LDH (IU/L)

Maternal Mortality

Total

No

Yes

No.

%age

No.

%age

No.

%age

<600

74

53.24

0

0.00

74

52.86

601-800

40

28.78

0

0.00

40

28.57

>800

25

17.99

1

100.00

26

18.57

Total

139

100.00

1

100.00

140

100.00

Mean

661.158±273.9175

3217.000±0.000

679.414±348.0668

[i] p-value (Independent t-test) 0.001

In our study, we found that none of the patients with serum LDH levels below 600 IU/L experienced maternal mortality. Similarly, there were no cases of maternal mortality among patients with serum LDH levels between 601-800 IU/L. However, among patients with serum LDH levels exceeding 800 IU/L, 100% experienced maternal mortality, while 17.99% did not. The mean LDH level in patients with maternal mortality was 3217.000 ± 0.000 IU, significantly higher than the 661.158 ± 273.9175 IU observed in patients without maternal mortality. Our study demonstrated a significant correlation between heightened levels of serum LDH and the occurrence of maternal mortality.

Distribution of study participants according to the serum LDH levels and correlation with perinatal outcomes

Table 7

Correlation between serum LDH levels and IUGR

LDH (IU/L)

IUGR

Total

No

Yes

No.

%age

No.

%age

No.

%age

<600

66

64.08

8

21.62

74

52.86

601-800

29

28.16

11

29.73

40

28.57

>800

8

7.77

18

48.65

26

18.57

Total

103

100.00

37

100.00

140

100.00

Mean

603.301±243.7660

891.297±486.5150

679.414±348.0668

[i] p-value (Independent t-test) 0.001

In our study, we observed that among patients with serum LDH levels below 600 IU/L, 21.62% had intrauterine growth restriction (IUGR), while 64.08% did not. For those with serum LDH levels between 601-800 IU/L, 29.73% had IUGR, and 28.16% did not. Among patients with LDH levels exceeding 800 IU/L, 48.65% had IUGR, and 7.77% did not. Our findings indicate a significant correlation between heightened levels of serum LDH and the occurrence of IUGR.

Table 8

Correlation between serum LDH levels and IUD

LDH (IU/L)

IUD

Total

No

Yes

No.

%age

No.

%age

No.

%age

<600

72

53.73

2

33.33

74

52.86

601-800

39

29.10

1

16.67

40

28.57

>800

23

17.16

3

50.00

26

18.57

Total

134

100.00

6

100.00

140

100.00

Mean

646.664±245.9982

1410.833±1042.8652

679.414±348.0668

[i] p-value (Independent t-test) 0.001

In our study, we observed that among patients with serum LDH levels below 600 IU/L, 33.33% had IUD, while 53.73% did not. For those with serum LDH levels between 601-800 IU/L, 16.67% had IUD, and 29.10% did not. Among patients with LDH levels exceeding 800 IU/L, 50% had IUD, and 17.16% did not. Our findings indicate a significant correlation between heightened levels of serum LDH and the occurrence of IUD.

Discussion

In our study, patients with serum levels of LDH below 600 IU/L mean SBP was 143 mmhg and DBP was 97, LDH levels between 601-800 mean SBP was 152 mmhg and mean DBP was 104 mmhg and in patients with serum LDH levels exceeding 800 ,mean SBP was 160 mmhg and DBP was 110 mmhg. There was significant association with raised LDH levels with high blood pressure.

Gupta et al.9 conducted a study in 2019, majority of the patients with serum levels of LDH below 600, SBP was </=140mmhg and DBP was </= 90 mmhg, in patients with LDH levels between 601-800 SBP was 140-<160 mmhg and DBP was 90-<110 mmhg and in patients with LDH levels >800, SBP was >160 mmhg and DBP was >110 mmhg. In this study also, there was significant association with heightened levels of serum LDH with high blood pressure.

Serum LDH levels in preeclamptic-eclamptic pregnant women group

In the present study, LDH levels greater than 800 IU/L were found in 75% of patients in the eclampsia group (6 patients), 37.25% of patients in the severe preeclampsia group (19 patients), and 1.23% of patients in the mild preeclampsia group (1 patient). Additionally, LDH levels between 601 and 800 IU/L were noted in 43.14% of patients with severe preeclampsia (22 patients), 25% of patients with eclampsia (2 patients) and 19.75% of patients with mildly preeclampsia (16 patients). The mean serum LDH levels were 1495.000±859.1230 IU/L in the eclampsia group, 804.569±224.5519 IU/L in the severe preeclamptic group, and 520.062±110.3944 IU/L in the mild preeclampsia group.

In a study conducted by Eleti et al.10 in 2023, it was found that serum levels of LDH exceeding 800 IU/L were significantly more in the eclamptic group (60% or 9 patients), in the severely preeclampsia group (40% or n=16 patients), and the mildly preeclamptic group (10% or n=6 patients), with none in the normotensive group (p < 0.0001). Similarly, LDH levels between 600 and 800 IU/L were significantly higher in the severe preeclampsia group (37.5% or 15 patients), the eclampsia group (33.33% or 5 patients), and the mild preeclampsia group (21.66% or 13 patients) compared to the normotensive group (1.73% or 2 patients) (p < 0.0001). The mean serum LDH levels in eclamptic group was 1515.86 ± 754.13 IU/L, 932.20 ± 448.28 IU/L in the severely preeclampsia group, and 580.56 ± 213.21 IU/L in the mildly preeclampsia group.

In a study by Jaiswar et al.11 in 2011, it was observed that most patients with mildly preeclampsia had LDH levels below 600 IU/L, with a mean value of 278.3 ± 119.2 IU/L. Only two(n=2) patients (5.7%) had serum levels of LDH between 600 and 800 IU/L, with a mean LDH level of 400.45 ± 145.21 IU/L. Among the 36 cases of severe preeclampsia, 58.3% (21 cases) had serum levels of LDH below 600 IU/L, 13.9% (5 cases) had levels between 600 and 800 IU/L, and 27.7% (10 cases) had levels more than 800 IU/L, with a mean LDH level of 646.95 ± 401.64 IU/L. In the eclampsia group, 69.4% (25 patients) had levels above 800 IU/L, 19.4% (7 patients) had levels of serum LDH between 600 and 800 IU/L, and 11.1% (4 patients) had levels of LDH below 600 IU/L, with a mean LDH level of 1648.10 ± 1992.29 IU/L. The data clearly indicate a significant raise in serum LDH levels with the complication of disease (P<0.001).

Serum LDH and maternal complications

In our study, we observed that Among patients with serum levels of LDH below 600 IU/L, there were 3 (15.79%) cases of abruptio, no cases of HELLP syndrome and no maternal mortality. In the group with serum LDH levels between 601 and 800 IU/L, there were 6 (31.58%) cases of abruptio, 1(20%) case of HELLP syndrome, and no maternal mortality. For patients with LDH levels exceeding 800 IU/L, there were 10(52.63%) cases of abruptio, 4 (80%) cases of HELLP syndrome, and 1(100%) maternal mortality.

The findings of our study align with those of Jaiswar et al. 11 who reported that only one case of abruptio placenta occurred in patients with serum levels of LDH between 600-800 IU/L. In contrast, among those with LDH levels exceeding 800 IU/L, there were eight cases of abruptio placenta, HELLP syndrome and pulmonary edema. Similar to our study, their study also demonstrated a statistically significant correlation of raised incidence of maternal complications with higher serum levels of LDH (p < 0.001).

Mary et al.12 similarly found a raised incidence of maternal complications with increasing serum levels of LDH. In their study, 94.3% of patients with serum levels of LDH greater than 800 IU/L developed complications, including eclampsia (38.8%), abruptio placenta (22.2%), HELLP syndrome (11.1%).In comparison, 13.6% of patients with LDH levels between 600-800 IU/L experienced complications such as eclampsia (6.8%) and abruptio placenta (3.4%), with these findings also being statistically significant. High serum levels of LDH were strongly correlated with significant impairments in renal and liver function.

Prajapati and Maitra et al.13 also documented a raised incidence of maternal adverse outcomes with rising serum levels of LDH. In their study, among patients with LDH levels greater than 800 IU/L, 36.3% developed eclampsia, 12.12% experienced abruptio placenta, 62.5% had HELLP syndrome, 24.24% required maternal ICU admission, and 3.03% resulted in maternal death. The majority (62.5%) of cases with LDH levels greater than 800 IU/L had complications (p < 0.001). In the same study, for LDH levels between 600-800 IU/L, maternal complications included HELLP syndrome (8.33%), abruptio placenta (4.1%), pulmonary edema (4.1%), and maternal ICU admission (4.16%). For LDH levels below 600 IU/L, complications included HELLP syndrome (2.02%), eclampsia (5.05%) and abruptio placenta (2.02%).

Perinatal outcome

In our study, 7.84% of patients with severe preeclampsia experienced intrauterine demise, while 25% of patients with eclampsia had intrauterine demise. P-value is significant.

Panda et al.14 conducted the study reported that 60 cases, accounting for 14.9%, resulted in perinatal mortality. This rate was significantly higher among women with eclampsia and severe preeclampsia, with a p-value of less than 0.0001, indicating strong statistical significance. Moreover, perinatal mortality was more prevalent in cases of eclampsia compared to severe preeclampsia, also with a p-value of less than 0.0001.

Serum LDH levels and its correlation with perinatal outcomes

In our study, In patients with LDH levels below 600 IU/L, there were 8 (21.62%) cases of intrauterine growth restriction (IUGR), 2(33.33%) cases of intrauterine death (IUD). For patients with LDH levels between 601-800 IU/L, there were 11(29.73%) cases of IUGR, 1 (16.67%) case of IUD, 13(37.14%) NICU admissions. In patients with serum levels of LDH exceeding 800 IU/L, there were 18 (48.65%)cases of IUGR, 3 (50%)cases of IUD, 20(57.14%) NICU admissions, The p-value is significant for all outcomes.

Eleti et al.10 conducted a study in 2023 observed the outcomes in patients with varying LDH levels. They found that among patients with serum levels of LDH below 600 IU/L, , 13 (26%) had intrauterine growth restriction (IUGR), and none had intrauterine death (IUD). In patients with serum levels of LDH between 600 and 800 IU/L, 17 (60.7%) experienced IUGR, and 1 (3.57%) had an IUD. Among those with LDH levels greater than 800 IU/L, 11 (50%) had IUGR, and 3 (13.6%) had an IUD.

According to Gupta et al.,9 in 2019, low birth weight occurred in 21(39.6%), with LDH levels below 600 IU/L. In patients with LDH levels between 600-800 IU/L, 18(66%) had low birth weight. In patients with LDH levels above 800 IU/L,17(85%) had low birth weight.

Lavanya et al.15 in 2021 reported that 4(7.8%) intrauterine growth restriction (IUGR),1(2%) had intrauterine fetal demise in patients with LDH levels below 600 IU/L.1(3.4%)intrauterine growth restriction (IUGR),none of the patient had intrauterine fetal demise in patients with LDH levels between 600-800 IU/L.3(15%) had IUGR with LDH levels above 800 IU/L.

Conclusion

The conclusion is that a crucial biochemical marker that indicates the severity of pre-eclampsia and eclampsia is lactate dehydrogenase. Women belonging to the preeclamptic-eclamptic group had greater serum LDH levels. Elevated levels of liver disease-related hemolysis (LDH) were linked to worse outcomes for mothers, including placental abruption, hemolysis, elevated liver enzymes, low platelet count (HELLP), and maternal death. Fetal complications, such as intrauterine fetal death (IUFD) and Intrauterine growth restriction (IUGR) were also be associated with higher serum levels of LDH. Raised LDH levels are also indicative of organ damage, as seen by elevated urine albumin in preeclamptic and eclamptic individuals. Increased levels of serum LDH should be detected and should prompt tight monitoring, scheduled delivery, and quick management to reduce the risk of major bad outcomes for both the mother and the fetus, as well as potential reductions in morbidity and mortality for both.

Source of Funding

None.

Conflict of Interest

None.

References

1 

E Abalos C Cuesta G Carroli Z Qureshi M Widmer JP Vogel Pre-eclampsia, eclampsia and adverse maternal and perinatal outcomes: a secondary analysis of the World Health Organization Multicountry Survey on Maternal and Newborn HealthBJOG201412111424

2 

FOGSI-GESTOSIS-ICOG hypertensive disorders of pregnancy good clinical practice recommendations201922https://www.fogsi.org/fogsi-hdp-gcpr-2019/

3 

FOGSI’s GCPR on Hypertensive Disorders in Pregnancy (HDP) 20192019https://www.fogsi.org/fogsi-hdp-gcpr-2019/

4 

L Myatt RG Clifton JM Roberts CY Spong JC Hauth MW Varner Can changes in angiogenic biomarkers between the first and second trimesters of pregnancy predict development of pre-eclampsia in a low-risk nulliparous patient population?BJOG201212010118391

5 

CB Dashe Hypertensive disorders of pregnancyWilliams Obstetrics25th edMcGraw-Hill Education/Medical2018668

6 

Lactate dehydrogenase (LDH), serum2024https://www.Mayocliniclabs.com/test-catalog/overview/8344

8 

HS Deeksha S Pajai MR Eleti VU Navalihiremath A Comprehensive Review on Serum Lactate Dehydrogenase (LDH) and Uric Acid in Preeclampsia: Implications for Maternal Health and Disease SeverityCureus202416356928

9 

N Bhandari A Gupta S Kharb M Chauhan Lactate dehydrogenase levels in preeclampsia and its correlation with maternal and perinatal outcomeInt J Reprod Contracept Obstet Gynecol2019841505510

10 

MR Eleti M Agrawal D Dewani N Goyal Serum LDH Levels in Normotensive and Preeclamptic-Eclamptic Pregnant Women and Its Correlation With Fetomaternal OutcomeCureus2023154e37220

11 

SP Jaiswar A Gupta R Sachan SN Natu M Shaili Lactic dehydrogenase: a biochemical marker for preeclampsia-eclampsiaJ Obstet Gynaecol India20126166458

12 

VP Mary M Chellatamizh S Padmanaban Role of serum LDH in preeclampsia as a prognostic factor - a cross sectional case control study in tertiary care hospitalInt J Reprod Contracept Obstet Gynecol201765958

13 

SR Prajapati N Maitra Prediction of pre-eclampsia by a combination of maternal history, uterine artery Doppler, and mean arterial pressure (a prospective study of 200 cases)J Obstet Gynaecol India2013631326

14 

S Panda R Das N Sharma A Das P Deb K Singh Maternal and perinatal outcomes in hypertensive disorders of pregnancy and factors influencing it: A prospective hospital-based study in Northeast IndiaCureus2021133e13982

15 

B Lavanya R Ullagaddi MK Pavani MS Rao Evaluation of serum lactate dehydrogenase as early diagnostic biomarker in pregnancy with preeclampsia and eclampsiaIndian J Obstet Gynecol Res202291837



jats-html.xsl


This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Article type

Original Article


Article page

600-606


Authors Details

Neha Kumari*, Ripan Bala, Sangeeta Pahwa


Article History

Received : 16-06-2024

Accepted : 17-07-2024


Article Metrics


View Article As

 


Downlaod Files